{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+intravenous+doses+of+placebo&page=10",
    "query": {
      "intervention": "Single intravenous doses of placebo",
      "page": 10
    },
    "page_size": 10
  },
  "pagination": {
    "page": 10,
    "page_size": 10,
    "total_count": 677,
    "total_pages": 68,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+intravenous+doses+of+placebo&page=11&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+intravenous+doses+of+placebo&page=9&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T21:53:25.797Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02127970",
      "title": "Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Abscess",
        "Wound Infection",
        "Surgical Site Infection",
        "Cellulitis"
      ],
      "interventions": [
        {
          "name": "Dalbavancin",
          "type": "DRUG"
        },
        {
          "name": "Dalbavancin-matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Durata Therapeutics Inc., an affiliate of Allergan plc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 698,
      "start_date": "2014-04-18",
      "completion_date": "2015-03-11",
      "has_results": true,
      "last_update_posted_date": "2018-09-28",
      "last_synced_at": "2026-10-14T21:53:25.797Z",
      "location_count": 25,
      "location_summary": "Montgomery, Alabama • Anaheim, California • Long Beach, California + 18 more",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Modesto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02127970"
    },
    {
      "nct_id": "NCT00911170",
      "title": "PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cancer",
        "Colon Cancer",
        "Colorectal Cancer",
        "Fever",
        "Locally Advanced",
        "Metastatic Colorectal Cancer",
        "Neutropenia",
        "Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "Pegfilgrastim",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard Chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 847,
      "start_date": "2009-11-03",
      "completion_date": "2015-01-02",
      "has_results": true,
      "last_update_posted_date": "2017-12-29",
      "last_synced_at": "2026-10-14T21:53:25.797Z",
      "location_count": 72,
      "location_summary": "Muscle Shoals, Alabama • Jonesboro, Arkansas • Anaheim, California + 66 more",
      "locations": [
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Modesto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00911170"
    },
    {
      "nct_id": "NCT00402350",
      "title": "Staccato Fentanyl Single and Multidose PK",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breakthrough Pain"
      ],
      "interventions": [
        {
          "name": "Inhaled Placebo",
          "type": "DRUG"
        },
        {
          "name": "Inhaled Fentanyl 25 mcg",
          "type": "DRUG"
        },
        {
          "name": "Intravenous Fentanyl 25 mcg",
          "type": "DRUG"
        },
        {
          "name": "Inhaled Fentanyl 25 mcg x 2",
          "type": "DRUG"
        },
        {
          "name": "Inhaled Fentanyl 25 mcg x 4",
          "type": "DRUG"
        },
        {
          "name": "Inhaled Fentanyl 25 mcg x 6",
          "type": "DRUG"
        },
        {
          "name": "Inhaled Fentanyl 25 mcg x 12",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexza Pharmaceuticals, Inc.",
      "sponsor_class": "UNKNOWN",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 51,
      "start_date": "2006-04",
      "completion_date": "2006-11",
      "has_results": false,
      "last_update_posted_date": "2017-03-15",
      "last_synced_at": "2026-10-14T21:53:25.797Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00402350"
    },
    {
      "nct_id": "NCT06072157",
      "title": "Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Subjects With Chronic Spontaneous Urticaria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants",
        "Chronic Spontaneous Urticaria"
      ],
      "interventions": [
        {
          "name": "AK006-IV",
          "type": "DRUG"
        },
        {
          "name": "Placebo-IV",
          "type": "DRUG"
        },
        {
          "name": "AK006-SC",
          "type": "DRUG"
        },
        {
          "name": "Placebo-SC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allakos Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 136,
      "start_date": "2023-08-28",
      "completion_date": "2025-05-12",
      "has_results": false,
      "last_update_posted_date": "2025-06-03",
      "last_synced_at": "2026-10-14T21:53:25.797Z",
      "location_count": 19,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 16 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06072157"
    },
    {
      "nct_id": "NCT02710669",
      "title": "New Formulations of Propafenone to Treat Atrial Fibrillation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Atrial Fibrillation"
      ],
      "interventions": [
        {
          "name": "(R)-propafenone",
          "type": "DRUG"
        },
        {
          "name": "(S)-Propafenone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 193,
      "start_date": "2016-10",
      "completion_date": "2020-04",
      "has_results": true,
      "last_update_posted_date": "2022-06-03",
      "last_synced_at": "2026-10-14T21:53:25.797Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02710669"
    },
    {
      "nct_id": "NCT04476901",
      "title": "Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-ischemic Dilated Cardiomyopathy"
      ],
      "interventions": [
        {
          "name": "allogeneic human mesenchymal stem cells (hMSCs)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Joshua M Hare",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 107,
      "start_date": "2021-05-07",
      "completion_date": "2027-04",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-10-14T21:53:25.797Z",
      "location_count": 4,
      "location_summary": "Stanford, California • Miami, Florida • Louisville, Kentucky + 1 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04476901"
    },
    {
      "nct_id": "NCT02095171",
      "title": "Single Ascending Dose Study of PRX002 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "PRX002",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Prothena Biosciences Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 40,
      "start_date": "2014-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2015-02-10",
      "last_synced_at": "2026-10-14T21:53:25.797Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02095171"
    },
    {
      "nct_id": "NCT06582602",
      "title": "A Study of MK-2060 in Healthy Participants (MK-2060-016)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Venous Thrombosis"
      ],
      "interventions": [
        {
          "name": "MK-2060",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 23,
      "start_date": "2024-10-15",
      "completion_date": "2025-04-18",
      "has_results": false,
      "last_update_posted_date": "2025-05-21",
      "last_synced_at": "2026-10-14T21:53:25.797Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Knoxville, Tennessee",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06582602"
    },
    {
      "nct_id": "NCT07306754",
      "title": "A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ABBV-243 in Healthy Adults.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "ABBV-243",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 66,
      "start_date": "2025-12-17",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2026-01-12",
      "last_synced_at": "2026-10-14T21:53:25.797Z",
      "location_count": 1,
      "location_summary": "Grayslake, Illinois",
      "locations": [
        {
          "city": "Grayslake",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07306754"
    },
    {
      "nct_id": "NCT01499420",
      "title": "A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stable Atherothrombotic Disease"
      ],
      "interventions": [
        {
          "name": "CSL112 (reconstituted high density lipoprotein)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "CSL Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 45,
      "start_date": "2012-02",
      "completion_date": "2013-03",
      "has_results": false,
      "last_update_posted_date": "2014-02-06",
      "last_synced_at": "2026-10-14T21:53:25.797Z",
      "location_count": 11,
      "location_summary": "Chula Vista, California • Jacksonville, Florida • Miami, Florida + 8 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Madisonville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01499420"
    }
  ]
}